New Study Establishes the Ability of Aspirin to Reduce Pancreatic Cancer Risk

Published Date : Jun 26, 2014

A latest study has revealed that the regular use of aspiring could reduce by half the risk of pancreatic cancer. This marks yet another addition to the existing list of lethal malignancies that can potentially be prevented by the inexpensive pill.

As part of the study, male and female participants who were administered a low dose of aspirin (75 to 325 mg) on a daily basis – primarily to prevent cardiovascular diseases – also showed a reduced pancreatic cancer risk. The study was published in the journal Cancer Epidemiology, Biomarkers & Prevention, which is published by the American Association for Cancer Research. Results from the study showed that consuming aspiring on a regular basis for nearly 10 years reduced the risk of pancreatic cancer by 60%.

While aspiring is typically prescribed to cut down the risk of cardiovascular disease, separate studies have also found that taking this inexpensive medicine daily could prevent cancers of the lung, colon, esophagus, and prostate gland. According to Harvey Risch, a senior author on the study, current estimates show that nearly one in every 60 adults has a high risk of developing pancreatic cancer. The disease has a low survival rate, and this makes it imperative for researchers to find a way to prevent its onset. According to researchers, cancer of the pancreas is the 10th most-common type of cancer in the United States as far as new cases are concerned. But in terms of mortality, it is the fourth highest. Estimates of the National Cancer Institute also show that nearly 46,000 new cases of pancreatic cancer are likely to be diagnosed in 2014, and the death rate may be 40,000 people.

According to researchers on this study, more investigations are required to determine how aspirin works to cut the risk of pancreatic cancer. However, it is possible that the drug may reduce cancer by lowering the risk of inflammation.